These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25987676)

  • 1. Ivabradine approved for stable chronic heart failure.
    Traynor K
    Am J Health Syst Pharm; 2015 Jun; 72(11):896. PubMed ID: 25987676
    [No Abstract]   [Full Text] [Related]  

  • 2. Ivabradine (Corlanor) for heart failure.
    Med Lett Drugs Ther; 2015 May; 57(1469):75-6. PubMed ID: 25989196
    [No Abstract]   [Full Text] [Related]  

  • 3. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Fast Track" Development and Approval Process for Heart Failure Therapeutics.
    Papadimitriou L; Butler J
    Clin Pharmacol Ther; 2017 Aug; 102(2):184-186. PubMed ID: 28636191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivabradine: Heart Failure and Beyond.
    Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
    Lim WY; Woldman S
    Br J Hosp Med (Lond); 2013 Feb; 74(2):C18-22. PubMed ID: 23411909
    [No Abstract]   [Full Text] [Related]  

  • 8. Ivabradine: Do the Benefits Outweigh the Risks?
    Alshammari TM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):210-218. PubMed ID: 27698078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine: Role in the Chronic Heart Failure Armamentarium.
    Psotka MA; Teerlink JR
    Circulation; 2016 May; 133(21):2066-75. PubMed ID: 27217432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine in Management of Heart Failure: a Critical Appraisal.
    Orasanu G; Al-Kindi SG; Oliveira GH
    Curr Heart Fail Rep; 2016 Feb; 13(1):60-9. PubMed ID: 26797824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivabradine for heart failure: regulatory differences in Europe and United States.
    Marciniak TA; Hall TS; Atar D; Agewall S; Serebruany VL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):119-121. PubMed ID: 30715322
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
    Elder DH; Mohan M; Cochrane L; Charles H; Lang CC
    Cardiovasc Ther; 2015 Jun; 33(3):104-8. PubMed ID: 25809454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use and Indication of Ivabradine in Heart Failure.
    Dodd K; Lampert BC
    Heart Fail Clin; 2018 Oct; 14(4):493-500. PubMed ID: 30266358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which place for ivabradine in Duchenne muscular dystrophy with heart failure?
    Fayssoil A
    Int J Cardiol; 2016 Nov; 223():768-769. PubMed ID: 27573604
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials.
    Mengesha HG; Weldearegawi B; Petrucka P; Bekele T; Otieno MG; Hailu A
    BMC Cardiovasc Disord; 2017 Apr; 17(1):105. PubMed ID: 28454527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
    Kansal AR; Cowie MR; Kielhorn A; Krotneva S; Tafazzoli A; Zheng Y; Yurgin N
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27153871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivabradine and outcomes in chronic heart failure.
    Kang SM; Won H; Hong N; Oh J
    Lancet; 2010 Dec; 376(9758):2069; author reply 2069-70. PubMed ID: 21168043
    [No Abstract]   [Full Text] [Related]  

  • 20. Ivabradine: A Current Overview.
    Guha K; Allen CJ; Hartley A; Sharma R
    Curr Clin Pharmacol; 2016; 11(4):241-249. PubMed ID: 27784216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.